Design, Synthesis and Biological Evaluation of 2, 4, 5-Triphenylimidazole Derivatives with Preliminary SAR
作者:Chunqi Hu、Jianfeng Shen、Kejun Bian、Ruoyu Zhang、Liping Deng
DOI:10.2174/1570180811666140116214111
日期:2014.5.31
A series of N1-substituted 2,4,5-triphenyl imidazole derivatives was designed, synthesized and evaluated for
their p53-MDM2 binding inhibitory activities and anti-proliferative activities in vitro against four human cancer cell lines
(PC3, KB, A549 and HCT116). Although logical evaluation revealed weak p53-MDM2 binding inhibitory activities, most
of the obtained molecules displayed moderate to potent cytotoxicities against tested cell lines. As a potential lead compound
for further optimization, compound 9c was evaluated as the most potent compound against four cell lines and could
induce cell cycle arrest at G2/M phase. The binding mode of compound 9f and MDM2 was further studied by docking
analysis and the unexpected interaction mode revealed that this series of compounds may take part into a different binding
modes as the lead compound Such as Nutlin, which could induce a different mechanism in cancer therapy.
设计、合成了系列N1取代的2,4,5-三苯基咪唑衍生物,并评价了其对 p53-MDM2 结合抑制活性及体外对人癌细胞系(PC3、KB、A549 和 HCT116)的抗增殖活性。虽然初步评估显示其对 p53-MDM2结合抑制活性较弱,但大部分所得化合物对被测细胞系显示出中等至强效的细胞毒性。作为潜在先导化合物,9c 在四条细胞系中表现出了最强的活性,并能诱导 G2/M 期细胞周期阻滞。进一步通过对接分析研究了 9f 与 MDM2 的结合模式,出乎意料的相互作用模式揭示了这一系列化合物可能采用了与 Nutlin等先导化合物不同的结合方式,从而在癌症治疗中诱导不同的机制。